Supplementary Table S7: Analysis of tumor mutational burden

Cancer Type	Cohort	Dose level	Best overall response	TMB Score (Mutations/Mb)	TMB Subgroup
Melanoma	Expansion Combination	DL8	iPR	2.0	Low
Melanoma	Expansion Combination	DL8	iCPD	4.0	Low
Melanoma	Escalation Combination	DL8	iPR	6.0	Intermediate
Basal Cell Carcinoma	Escalation Combination	DL8	iSD	6.0	Intermediate
Melanoma	Expansion Combination	DL8	iSD	6.0	Intermediate
Melanoma	Expansion Combination	DL8	iSD	7.0	Intermediate
Melanoma	Expansion Combination	DL8	iUPD	9.0	Intermediate
Melanoma	Escalation Combination	DL7	iCPD	14.0	High
Melanoma	Expansion Combination	DL8	iUPD	14.0	High
Melanoma	Escalation Combination	DL8	iCPD	17.0	High
Unknown	Expansion Combination	DL8	iCPD	19.0	High

iCPD, immune confirmed progressive disease; iPR, immune partial response; iSD, immune stable disease; iUPD, immune unconfirmed progressive disease; DL, dose level; TMB, tumor mutational burden.